Skip to main content

Table 5 Demographic and clinical characteristics for the different genotypes of rs55646866 in CD patients

From: Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients

 

rs55646866

CC

rs55646866

CT

rs55646866

TT

p value (Fisher or Kruskal–Wallis)

Gender

 Male (n = 488)

 Female (n = 493)

394 (50.2%)

391 (49.8%)

81 (46.8%)

92 (53.2%)

13 (56.5%)

10 (43.5%)

0.605

Age at diagnosis [years]

 Median, q25q75,

 Minmax

24.3, 17.9–34.4,

1.1–81.4

24.4, 18.5–33.0,

0.8–65.9

25.0, 18.7–31.5,

11.5–73.7

0.875

Disease duration [years]

 Median, q25q75,

 Minmax

12.2, 7.0–20.9,

0.1–56.6

12.8, 7.6–23.5,

1.2–44.7

6.1, 4.5–13.1,

1.5–33.8

0.030

Complications*

 No (n = 345)

 Yes (n = 636)

281 (35.8%)

504 (64.2%)

56 (32.4%)

117 (67.6%)

8 (34.8%)

15 (65.2%)

0.727

Fistula, abscess or anal fissure*

 No (n = 518)

 Yes (n = 463)

411 (52.4%)

374 (47.6%)

94 (54.3%)

79 (45.7%)

13 (56.5%)

10 (43.5%)

0.836

Focus on the “yes”:

 Perianal fistula

 Other fistula

 Fissure

 Abscess

199 (53.2%)

144 (38.5%)

113 (30.2%)

203 (54.3%)

38 (48.1%)

36 (45.6%)

24 (30.4%)

44 (55.7%)

6 (60.0%)

3 (30.0%)

3 (30.0%)

6 (60.0%)

0.641

0.439

1.000

0.930

 Surgery

195 (52.1%)

46 (58.2%)

5 (50.0%)

0.626

Stenosis*

 No (n = 551)

 Yes (n = 430)

446 (56.8%)

339 (43.2%)

95 (54.9%)

78 (45.1%)

10 (43.5%)

13 (56.5%)

0.413

Focus on the “yes”:

 Operation

 Dilation

 No intervention

169 (49.9%)

133 (39.2%)

189 (55.8%)

44 (56.4%)

33 (42.3%)

40 (51.3%)

8 (61.5%)

3 (23.1%)

7 (53.8%)

0.460

0.434

0.766

CDAI—maximal value throughout follow-up

 Median, q25q75,

 Minmax

64, 28–114,

0–435

76, 33–131,

6–479

64, 50–117,

6–280

0.108

Reported flare*

 No (n = 477)

 Yes (n = 504)

387 (49.3%)

398 (50.7%)

82 (47.4%)

91 (52.6%)

8 (34.8%)

15 (65.2%)

0.365

Flare possibly or highly related to (focus on yes):

 NSAIDs

 Antibiotics

 GI tract infection

 Other infection

 Treatment decr./disc

 Other medication

8 (2.0%)

8 (2.0%)

63 (15.8%)

25 (6.3%)

100 (25.1%)

4 (1.0%)

2 (2.2%)

0 (0%)

20 (22.0%)

11 (12.1%)

29 (31.9%)

3 (3.3%)

1 (6.7%)

1 (6.7%)

1 (6.7%)

1 (6.7%)

5 (33.3%)

0 (0%)

0.450

0.154

0.255

0.143

0.319

0.292

Flare management (focus on the yes):

 Hospitalization

 Ambulatory

 Surgery

 Drug therapy

68 (17.1%)

96 (24.1%)

39 (9.8%)

344 (86.4%)

16 (17.6%)

31 (34.1%)

11 (12.1%)

81 (89.0%)

2 (13.3%)

2 (13.3%)

0 (0%)

13 (86.7%)

0.967

0.090

0.443

0.776

Focus on the hospitalizations:

 Total days of hosp.

 Median, q25q75,

 Minmax

7.5, 2–16,

0–55

3.5, 0–17.5,

0–86

4, 3–5,

3–5

0.553

  1. Bold indicates a significant p-value (p < 0.05)